[Federal Register Volume 67, Number 143 (Thursday, July 25, 2002)]
[Notices]
[Page 48664]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-18775]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Request for Nominations for Nonvoting Representatives of Industry 
Interests on Public Advisory Committees

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is requesting 
nominations for nonvoting representatives of industry interests to 
serve on the Blood Products Advisory Committee, in the Center for 
Biologics Evaluation and Research (CBER). Nominations will be accepted 
for vacancies that will or may occur through September 30, 2003.
    FDA has a special interest in ensuring that women, minority groups, 
individuals with disabilities, and small businesses are adequately 
represented on advisory committees and, therefore, encourages 
nominations for appropriately qualified candidates from these groups. 
Specifically, in this document, nominations for nonvoting 
representatives of industry interests are encouraged from the biologics 
and/or drug industry.

DATES: Nominations should be received by July 30, 2002.

ADDRESSES: All nominations and curricula vitae should be sent to Linda 
A. Smallwood (see FOR FURTHER INFORMATION CONTACT).

FOR FURTHER INFORMATION CONTACT: Linda A. Smallwood, Office of Blood 
Research and Review, Center for Biologics Evaluation and Research (HFM-
350), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 
20852-1448, 301-827-6128.

SUPPLEMENTARY INFORMATION: Section 120 of the FDA Modernization Act 
(FDAMA) of 1997 (21 U.S.C. 355) requires that newly formed FDA advisory 
committees include representatives from the biologics and/or drug 
manufacturing industries. This announcement is soliciting nominations 
for the committee listed below:
    Blood Products Advisory Committee: One vacancy occurring in 
September 30, 2002; clinical and administrative medicine, hematology, 
immunology, blood banking, surgery, internal medicine, biochemistry, 
engineering, statistics, biological and physical sciences, and other 
related scientific fields.

I. Function

    Reviews and evaluates available data concerning the safety, 
effectiveness, and appropriate use of blood and products intended for 
use in the diagnosis, prevention, or treatment of human diseases.

II. Nomination Procedures

    Any organization in the blood, medical device and/or biologics 
manufacturing industry wishing to participate in the selection of an 
appropriate nonvoting industry representative for the Blood Products 
Advisory Committee should notify the contact person of their interest 
in nominating one or more qualified persons. Persons who nominate 
themselves as representatives of industry interests for a certain 
advisory committee may not participate in the overall selection 
process.
    Nominees should be familiar with firms that manufacture products 
regulated by the agency including biologics and/or drug manufacturers. 
Nomination packages should include the name of the committee and the 
nominee's willingness to serve on the committee. To ensure that the 
nomination process continues within the set timelines, submitters are 
strongly encouraged to include a complete curriculum vitae for each 
nominee with the letter of nomination. The term of office is up to 4 
years.

III. Selection Procedure

    A letter will be sent to each nominating organization that 
submitted a nomination package to FDA for a particular advisory 
committee. The letter will provide the complete list of all nominees. 
It is the responsibility of each nominating organization to consult 
with one another to select a single member to represent the industry 
interests for the advisory committee. This must be completed within 60 
calendar days. If no individual is selected, the Commissioner of Food 
and Drugs will select a nonvoting member to represent the industry 
interests.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14 relating to advisory committees.

    Dated: July 18, 2002.
William K. Hubbard,
Senior Associate Commissioner for Policy, Planning, and Legislation.
[FR Doc. 02-18775 Filed 7-24-02; 8:45 am]
BILLING CODE 4160-01-S04